文献速递胸部肿瘤头颈与中枢神经肿瘤

劳拉替尼治疗经治ALK阳性晚期非小细胞肺癌:中国2期研究的主要疗效与安全性

Lorlatinib for Previously Treated ALK-Positive Advanced NSCLC: Primary Efficacy and Safety From a Phase 2 Study in People's Republic of China.
PubMed 文献 · J Thorac Oncol · 2022-03-17

这项在中国开展的开放标签双队列2期研究(NCT03909971)纳入109例经ALK酪氨酸激酶抑制剂治疗后进展的ALK阳性晚期或转移性非小细胞肺癌患者,口服劳拉替尼100 mg每日一次。队列1(既往克唑替尼,n=67)客观缓解率为70.1%(95%CI 57.7-80.7,p<0.0001),队列2(既往非克唑替尼的ALK酪氨酸激酶抑制剂±克唑替尼,n=42)为47.6%(95%CI 32.0-63.6)。基线脑病灶患者颅内客观缓解率队列1为80.6%,队列2为47.6%。

要点

  • 队列1经独立中心影像评估的客观缓解率为70.1%(95%CI 57.7-80.7,p<0.0001)。
  • 队列2客观缓解率为47.6%(95%CI 32.0-63.6)。
  • 基线脑病灶患者颅内客观缓解率队列1为80.6%,队列2为47.6%。

核心结论

  • 劳拉替尼在经治的中国ALK阳性非小细胞肺癌患者中显示出稳健而持久的缓解和高颅内客观缓解率。

研究设计与样本

  • 开放标签、双队列2期研究(NCT03909971),纳入经ALK酪氨酸激酶抑制剂治疗后进展的ALK阳性晚期或转移性非小细胞肺癌患者。
  • 队列1为既往克唑替尼治疗(n=67),队列2为既往一种非克唑替尼的ALK酪氨酸激酶抑制剂±既往克唑替尼(n=42)。
  • 患者需有至少一个未放疗的颅外靶病灶,东部肿瘤协作组体能状态评分为0至2。
  • 患者口服劳拉替尼100 mg每日一次,连续21天为一周期。
  • 主要终点为队列1经独立中心影像按实体瘤疗效评价标准1.1版评估的客观缓解;分析基于接受至少一剂治疗的患者。

主要发现

  • 数据截止2020年8月10日,共入组109例患者(队列1 n=67;队列2 n=42)。
  • 队列1有47例(70.1%,95%CI 57.7-80.7,p<0.0001)经独立中心影像评估达到客观缓解(主要终点)。
  • 队列2有20例(47.6%,95%CI 32.0-63.6)经独立中心影像评估达到客观缓解(次要终点)。
  • 队列1中位无进展生存期未达到,队列2为5.6个月。
  • 基线有脑病灶的患者中,队列1的36例中有29例(80.6%,95%CI 64.0-91.8)、队列2的21例中有10例(47.6%,95%CI 25.7-70.2)经独立中心影像评估达到颅内客观缓解。

关键数值与推荐

  • 队列1客观缓解率70.1%(95%CI 57.7-80.7,p<0.0001)。
  • 队列2客观缓解率47.6%(95%CI 32.0-63.6)。
  • 队列1颅内客观缓解率80.6%(95%CI 64.0-91.8),队列2为47.6%(95%CI 25.7-70.2)。
  • 高胆固醇血症(92.7%)和高甘油三酯血症(90.8%)(聚类术语)为常见治疗相关不良事件。
  • 9例(8.3%)发生严重治疗相关不良事件;1例因治疗相关不良事件永久停药。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Lorlatinib was found to have activity in ALK-positive NSCLC in a global phase 1 and 2 study. We report an ongoing phase 2 study in Chinese patients with ALK-positive advanced or metastatic NSCLC. METHODS: Open-label, dual-cohort study (NCT03909971); patients had progressive disease after ALK tyrosine kinase inhibitor treatment (cohort 1: previous crizotinib; cohort 2: one ALK tyrosine kinase inhibitor other than crizotinib [±prior crizotinib]), more than or equal to one unirradiated extracranial target lesion, and Eastern Cooperative Oncology Group performance status of 0 to 2. Patients received oral lorlatinib 100 mg once daily in continuous 21-day cycles. Primary end point: objective response in cohort 1 by independent central radiology (ICR) according to Response Evaluation Criteria in Solid Tumors version 1.1. Analyses were based on patients receiving more than or equal to one dose. RESULTS: At data cutoff (August 10, 2020), 109 patients were enrolled (cohort 1: n = 67; cohort 2: n = 42). A total of 47 patients in cohort 1 (70.1%, 95% confidence interval [CI]: 57.7-80.7, p < 0.0001; primary end point) and 20 patients in cohort 2 (47.6%, 95% CI: 32.0-63.6, secondary end point) achieved objective response by ICR. Median progression-free survival was not reached in cohort 1 and was 5.6 months in cohort 2. In patients with brain lesions at baseline, 29 of 36 patients in cohort 1 (80.6%, 95% CI: 64.0-91.8) and 10 of 21 patients in cohort 2 (47.6%, 95% CI: 25.7-70.2) achieved objective intracranial response by ICR. Hypercholesterolemia (92.7%) and hypertriglyceridemia (90.8%) (cluster terms) were common treatment-related adverse events (TRAEs). Nine patients (8.3%) had serious TRAEs; one permanently discontinued from treatment because of TRAEs. CONCLUSIONS: Lorlatinib was found to have a robust and durable response and high intracranial objective response in previously treated Chinese patients with ALK-positive NSCLC.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Lu S, Zhou Q, Liu X, et al. Lorlatinib for Previously Treated ALK-Positive Advanced NSCLC: Primary Efficacy and Safety From a Phase 2 Study in People's Republic of China. J Thorac Oncol. 2022. PMID: 35307611. doi:10.1016/j.jtho.2022.02.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。